Previous 10 | Next 10 |
Anavex Life Sciences press release (NASDAQ:AVXL): FQ1 GAAP EPS of -$0.14. Cash and cash equivalents of $151.1 million on December 31, 2021, compared to $152.1 million on September 30, 2021. For further details see: Anavex Life Sciences GAAP EPS of -$0.14
Company to host a webcast today at 4:30 p.m. Eastern Time NEW YORK, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated t...
Investing in the biotech industry is an art, not a science. While the potential for gains from groundbreaking therapies exists, the majority fail. By utilizing statistics, careful selection, and net present value calculations, it is quite easy to find a basket that fulfills your p...
Most treatments for Alzheimer's disease either lead to only temporary improvements in cognition or only minimally slow down the progression of the disease because they only inhibit peroxynitrite formation. Anavex 2-73 appears to almost stabilize Alzheimer's disease for long periods of...
Anavex Life Sciences (NASDAQ:AVXL), a clinical-stage biopharmaceutical Co., provides supplemental information on the ANAVEX®2-73 AVATAR Phase 3 trial for the treatment of adult patients with Rett syndrome. Based on the results of the AVATAR Phase 3 study and the prior successful U.S...
Snap (NYSE:SNAP) +40% on Q4 results. Bill.com Holdings (NYSE:BILL) +23% on Q2 results. Sphere 3D (NASDAQ:ANY) +16% on purchase of 60K Numiner NM440 BTC Miners. Unity Software (NYSE:U) +14% on Q4 results. Standard Lithium (NYSE:SLI) +12% set to rebound from short seller's s...
I investigate the reasoning behind Anvex Life Sciences' wild share price ride over the last year. The company’s lead compound Anavex 2-73 has a favorable safety profile, but what does the data show? I briefly touch on the companies Parkinson's disease therapy. For fur...
NEW YORK, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diso...
In its phase 3 clinical trial for female adult Rett syndrome, Anavex 2-73 produced results that were both clinically and statistically significant. Anavex and its investors were not rewarded for these results because the company had not announced that changes had been made in the outc...
AVXL reported positive topline data from their trial for Rett syndrome in adults on Feb 1, 2022. However, the results were met with much skepticism or cynicism, due to changes to the trial's endpoints, registered on the clinicaltrials.gov site that was submitted on Jan 18. AVXL CE...
News, Short Squeeze, Breakout and More Instantly...
Anavex Life Sciences Corp. Company Name:
AVXL Stock Symbol:
NASDAQ Market:
Anavex Life Sciences Corp. Website:
2024-07-18 02:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsyc...
NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsyc...